Startups
CMS Medical Venture Investment (HK) Limited
Hong Kong
CMS Medical Venture Investment (HK) Limited is the Hong Kong corporate investment-holding vehicle named as an actual shareholder and investor in healthcare and life-science companies. It is distinct from Cayman-incorporated China Medical System Holdings Limited, the group’s operating and listed parent, and from similarly named BVI and Singapore companies. A2019 joint SEC Schedule13D and2022 Gelesis Schedule13G confirm the Hong Kong vehicle as a wholly owned CMS subsidiary and direct holder of investments; indirect parent beneficial ownership is not a second paid check. The 2019 filing identifies its principal business address as Unit2106,21/F, IslandPlaceTower,510King’sRoad,NorthPoint,HongKong. Its published subsidiary governance comprises two named directors, LamKong and HuaizhengPeng, historically confirmed2019; Peng additionally signs its2022 filing as director. The current CMS group biographies independently identify Lam as group founder/chairman/chief executive and Peng as chief business officer, but those current parent positions are not asserted as new current subsidiary operating roles. This record uses authentic CMS group branding with explicit parent-brand qualification because no independently branded subsidiary logo or dedicated subsidiary site was located. A&B(HK)CompanyLimited and its BVI parent are separate investment entities associated with LamKong; they are not CMSHK aliases or automatically wholly owned CMS subsidiaries. In2019 CMSHK and A&BHK each independently paid approximately GBP4M for Midatech shares/warrants from their own working capital. The parent and Lam made no direct purchases in that transaction, and commercial licensing milestones are not equity cash. Midatech and Gelesis are historical portfolio evidence; historical holdings do not prove current ownership or a new financing. Actual2018 Acticor SeriesB participation is sourced by issuer release and linked separately, with individual check unknown. Acticor entered judicial liquidation in January2025; no clinical efficacy or current operation is implied by this historical investment. Corporate paid-up share capital, group AUM and partner license capacity are not LP fund closes. No pooled external fund vehicles, independent subsidiary staff directory or exact current subsidiary directors’ tenure were disclosed in the reviewed sources.
Team
 Huaizheng PengDirector (historical confirmed2019 and2022) |
 Lam KongDirector (historical subsidiary governance confirmed2019) |
